HRP20150470T1 - Topljivi icam-1 kao biomarker za predviđanje terapijskog odgovora - Google Patents
Topljivi icam-1 kao biomarker za predviđanje terapijskog odgovora Download PDFInfo
- Publication number
- HRP20150470T1 HRP20150470T1 HRP20150470TT HRP20150470T HRP20150470T1 HR P20150470 T1 HRP20150470 T1 HR P20150470T1 HR P20150470T T HRP20150470T T HR P20150470TT HR P20150470 T HRP20150470 T HR P20150470T HR P20150470 T1 HRP20150470 T1 HR P20150470T1
- Authority
- HR
- Croatia
- Prior art keywords
- sicam
- vector
- patient
- recombinant
- levels
- Prior art date
Links
- 239000000090 biomarker Substances 0.000 title claims 2
- 230000004797 therapeutic response Effects 0.000 title claims 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 title 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 title 1
- 238000000034 method Methods 0.000 claims 17
- 239000013598 vector Substances 0.000 claims 9
- 230000002163 immunogen Effects 0.000 claims 7
- 210000004369 blood Anatomy 0.000 claims 5
- 239000008280 blood Substances 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 239000013603 viral vector Substances 0.000 claims 3
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 238000012956 testing procedure Methods 0.000 claims 2
- 208000007089 vaccinia Diseases 0.000 claims 2
- 102000004506 Blood Proteins Human genes 0.000 claims 1
- 108010017384 Blood Proteins Proteins 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000012829 chemotherapy agent Substances 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Claims (16)
1. Postupak ispitivanja ex-vivo hoće li pacijent odgovoriti terapijski na postupak liječenja koji se sastoji u primjeni imunogenog pripravka, naznačen time što se postupak ispitivanja sastoji u koraku mjerenja razina sICAM-1 u uzorku krvi uzetom iz navedenog pacijenta prije primjene navedenog imunogenog pripravka, gdje niske razine sICAM-1 ukazuju da će pacijent razviti profilaktički ili terapijski odgovor na imunogeni pripravak kada su niske razine sICAM-1 ispod 300 ng/ml, te što navedeni imunogeni pripravak sadrži sve ili dio najmanje jednog ciljanog antigena ili najmanje jedan rekombinantni vektor koji in vivo eksprimira sve ili dio najmanje jednog heterolognog nukleotidnog slijeda koji kodira sve ili dio najmanje jednog ciljanog antigena.
2. Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedene niske razine sICAM-1 znače razine ispod 250 ng/ml.
3. Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedene niske razine sICAM-1 znače razine ispod 224 ng/ml.
4. Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedene niske razine sICAM-1 znače razine ispod 200 ng/ml.
5. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što je navedeni postupak liječenja postupak liječenja raka.
6. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se navedenu razina sICAM-1 mjeri multianalitnim profilranjem proteina plazme ili imunosorpcijska ispitivanja vezana s enzimima.
7. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se navedenu razinu sICAM-1 određuje uz pomoć protutijela.
8. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se navedeni uzorak krvi bira iz skupine koju čine uzorak pune krvi, plazme ili seruma.
9. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što je navedeni rekombinantni vektor virusni vektor.
10. Postupak u skladu s patentnim zahtjevom 9, naznačen time što je navedeni virusni vektor replikacijski kompetentan.
11. Postupak u skladu s patentnim zahtjevom 9, naznačen time što je navedeni virusni vektor replikacijski manjkav.
12. Postupak u skladu s bilo kojim od patentnih zahtjeva 9 to 11, naznačen time što je navedeni rekombinantni vektor rekombinantni adenovirusni vektor.
13. Postupak u skladu s bilo kojim od patentnih zahtjeva 9 to 11, naznačen time što je navedeni rekombinantni vektor rekombinantna vakcinija kao vektor.
14. Postupak u skladu s patentnim zahtjevom 13, naznačen time što je navedena rekombinantna vakcinija kao vektor rekombinantni MVA kao vektor.
15. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je navedeni pacijent pacijent liječen kemoterapijskim sredstvom.
16. Upotreba razina sICAM-1 u uzorku krvi kao biomarkera za predviđanje pokazuje li pacijent sklonost ili ne razvoju profilaktičkog ili terapijskog imunosnog odgovora kod primjene imunogenog pripravka, naznačena time što je navedeni uzorak krvi uzet iz navedenog pacijenta prije primjene imunogenog pripravka, te što navedeni imunogeni pripravak sadrži sve ili dio najmanje jednog ciljanog antigena ili najmanje jedan rekombinantni vektor koji in vivo eksprimira sve ili dio najmanje jednog heterolognog nukleotidnog slijeda koji kodira sve ili dio najmanje jednog ciljanog antigena.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09305044 | 2009-01-20 | ||
| EP09305294 | 2009-04-07 | ||
| EP10704115.4A EP2382474B1 (en) | 2009-01-20 | 2010-01-18 | Soluble icam-1 as biomarker for prediction of therapeutic response |
| PCT/EP2010/050532 WO2010084100A1 (en) | 2009-01-20 | 2010-01-18 | Soluble icam-1 as biomarker for prediction of therapeutic response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150470T1 true HRP20150470T1 (hr) | 2015-06-05 |
Family
ID=42028081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150470TT HRP20150470T1 (hr) | 2009-01-20 | 2015-05-04 | Topljivi icam-1 kao biomarker za predviđanje terapijskog odgovora |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20110312525A1 (hr) |
| EP (1) | EP2382474B1 (hr) |
| JP (1) | JP5379243B2 (hr) |
| KR (1) | KR20110116016A (hr) |
| CN (1) | CN102292638B (hr) |
| AU (1) | AU2010206195B2 (hr) |
| BR (1) | BRPI1006901A2 (hr) |
| CA (1) | CA2749192A1 (hr) |
| CO (1) | CO6390020A2 (hr) |
| CR (1) | CR20110438A (hr) |
| DK (1) | DK2382474T3 (hr) |
| ES (1) | ES2536747T3 (hr) |
| HK (1) | HK1161643A1 (hr) |
| HR (1) | HRP20150470T1 (hr) |
| HU (1) | HUE025015T2 (hr) |
| IL (1) | IL213098A (hr) |
| MX (1) | MX2011007386A (hr) |
| NZ (1) | NZ593749A (hr) |
| PL (1) | PL2382474T3 (hr) |
| PT (1) | PT2382474E (hr) |
| SG (2) | SG173065A1 (hr) |
| TW (1) | TWI440854B (hr) |
| WO (1) | WO2010084100A1 (hr) |
| ZA (1) | ZA201105271B (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103175959B (zh) * | 2013-02-28 | 2015-10-14 | 成都创宜生物科技有限公司 | 一种检测胎膜早破免疫层析试纸的制备方法 |
| CN103235134B (zh) * | 2013-05-08 | 2015-10-14 | 成都创宜生物科技有限公司 | 一种检测胎膜早破的免疫层析试纸及其制备方法 |
| CN103698537A (zh) * | 2014-01-06 | 2014-04-02 | 天津医科大学总医院 | 定量检测人血清可溶性细胞间粘附分子-1的化学发光免疫分析试剂盒及检测方法 |
| WO2019173462A1 (en) * | 2018-03-06 | 2019-09-12 | Pepvax, Inc. | Nucleic acid molecules and methods of using the same |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| FR2602790B1 (fr) * | 1986-08-13 | 1990-06-01 | Transgene Sa | Expression d'un antigene specifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement preventif ou curatif de la tumeur correspondante |
| FR2643817B1 (fr) | 1989-03-06 | 1993-12-17 | Transgene Sa | Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus |
| DE3642912A1 (de) | 1986-12-16 | 1988-06-30 | Leybold Ag | Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer |
| US6222020B1 (en) | 1987-01-07 | 2001-04-24 | Imperial Cancer Research Technology Limited | Antigens derived from the core protein of the human mammary epithelial mucin |
| ES2080044T3 (es) | 1987-05-04 | 1996-02-01 | Dana Farber Cancer Inst Inc | Moleculas de adhesion intercelular y sus ligandos de fijacion. |
| FR2632863B2 (fr) | 1987-10-29 | 1990-08-31 | Transgene Sa | Virus du fowlpox recombinant et vaccins derives de ces virus |
| CA2008368C (en) | 1989-01-24 | 2003-04-08 | Jeffrey Greve | Soluble molecule related to but distinct from icam-1 |
| US5100587A (en) | 1989-11-13 | 1992-03-31 | The United States Of America As Represented By The Department Of Energy | Solid-state radioluminescent zeolite-containing composition and light sources |
| FR2668064B1 (fr) | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
| US5756102A (en) | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| WO1992015672A1 (en) | 1991-03-07 | 1992-09-17 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US5179993A (en) | 1991-03-26 | 1993-01-19 | Hughes Aircraft Company | Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid |
| US6013638A (en) | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
| US6133028A (en) | 1993-05-28 | 2000-10-17 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| US5698443A (en) | 1995-06-27 | 1997-12-16 | Calydon, Inc. | Tissue specific viral vectors |
| US20030026782A1 (en) | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| CA2560114A1 (en) | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
| FR2727689A1 (fr) | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| DE69638058D1 (de) | 1995-06-15 | 2009-11-26 | Crucell Holland Bv | Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie |
| WO1998004727A1 (en) | 1996-07-25 | 1998-02-05 | Therion Biologics Corporation | Recombinant pox virus for immunization against tumor-associated antigens |
| FR2751879B1 (fr) | 1996-07-30 | 1998-10-30 | Transgene Sa | Composition pharmaceutique contre les tumeurs et infections a papillomavirus |
| AU727308B2 (en) | 1997-02-24 | 2000-12-07 | Dana-Farber Cancer Institute | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| US6900049B2 (en) | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
| US20020037274A1 (en) | 1998-10-26 | 2002-03-28 | Angelica Williams | Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants |
| FR2787465A1 (fr) | 1998-12-21 | 2000-06-23 | Transgene Sa | Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes |
| EP1147181B1 (en) | 1999-02-04 | 2004-05-12 | Geron Corporation | Replicative virus driven by the promoter for telomerase reverse transcriptase for use in treating cancer |
| EP1155120B1 (fr) | 1999-02-22 | 2006-07-05 | Transgene S.A. | Procede d'obtention d'une preparation virale purifiee |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| ES2288488T3 (es) | 1999-11-15 | 2008-01-16 | Onyx Pharmaceuticals, Inc. | Adenovirus oncoliticos. |
| AUPQ520800A0 (en) | 2000-01-21 | 2000-02-17 | Alfred Hospital | Prime-boost vaccination strategy |
| UA76731C2 (uk) | 2000-11-23 | 2006-09-15 | Баваріан Нордік А/С | Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації |
| GB0118532D0 (en) | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
| CN1753687A (zh) | 2002-10-29 | 2006-03-29 | 科勒制药集团股份有限公司 | Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用 |
| FR2855758B1 (fr) | 2003-06-05 | 2005-07-22 | Biomerieux Sa | Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique |
| FR2862648B1 (fr) | 2003-11-21 | 2006-02-03 | Biomerieux Sa | Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c |
| US7381536B2 (en) | 2005-03-01 | 2008-06-03 | Gurbel Paul A | Assessment of cardiac health and thrombotic risk in a patient |
-
2010
- 2010-01-18 ES ES10704115.4T patent/ES2536747T3/es active Active
- 2010-01-18 PL PL10704115T patent/PL2382474T3/pl unknown
- 2010-01-18 CA CA2749192A patent/CA2749192A1/en not_active Abandoned
- 2010-01-18 JP JP2011545757A patent/JP5379243B2/ja not_active Expired - Fee Related
- 2010-01-18 EP EP10704115.4A patent/EP2382474B1/en not_active Not-in-force
- 2010-01-18 DK DK10704115T patent/DK2382474T3/en active
- 2010-01-18 SG SG2011052404A patent/SG173065A1/en unknown
- 2010-01-18 NZ NZ593749A patent/NZ593749A/xx not_active IP Right Cessation
- 2010-01-18 BR BRPI1006901A patent/BRPI1006901A2/pt not_active Application Discontinuation
- 2010-01-18 AU AU2010206195A patent/AU2010206195B2/en not_active Ceased
- 2010-01-18 US US13/145,336 patent/US20110312525A1/en not_active Abandoned
- 2010-01-18 PT PT107041154T patent/PT2382474E/pt unknown
- 2010-01-18 CN CN201080004940.8A patent/CN102292638B/zh not_active Expired - Fee Related
- 2010-01-18 KR KR1020117016841A patent/KR20110116016A/ko active IP Right Grant
- 2010-01-18 MX MX2011007386A patent/MX2011007386A/es active IP Right Grant
- 2010-01-18 WO PCT/EP2010/050532 patent/WO2010084100A1/en active Application Filing
- 2010-01-18 SG SG2014004030A patent/SG196837A1/en unknown
- 2010-01-18 HU HUE10704115A patent/HUE025015T2/en unknown
- 2010-01-20 TW TW099101520A patent/TWI440854B/zh not_active IP Right Cessation
-
2011
- 2011-05-24 IL IL213098A patent/IL213098A/en not_active IP Right Cessation
- 2011-07-18 ZA ZA2011/05271A patent/ZA201105271B/en unknown
- 2011-07-19 CO CO11090083A patent/CO6390020A2/es not_active Application Discontinuation
- 2011-08-17 CR CR20110438A patent/CR20110438A/es not_active Application Discontinuation
-
2012
- 2012-02-29 HK HK12102112.5A patent/HK1161643A1/xx not_active IP Right Cessation
-
2013
- 2013-05-23 US US13/900,869 patent/US20140023686A1/en not_active Abandoned
-
2015
- 2015-05-04 HR HRP20150470TT patent/HRP20150470T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2382474B1 (en) | 2015-03-04 |
| MX2011007386A (es) | 2011-08-03 |
| CA2749192A1 (en) | 2010-07-29 |
| WO2010084100A1 (en) | 2010-07-29 |
| ES2536747T3 (es) | 2015-05-28 |
| IL213098A (en) | 2015-08-31 |
| CR20110438A (es) | 2011-12-28 |
| HK1161643A1 (en) | 2012-07-27 |
| US20110312525A1 (en) | 2011-12-22 |
| CN102292638B (zh) | 2014-05-28 |
| US20140023686A1 (en) | 2014-01-23 |
| AU2010206195B2 (en) | 2016-03-10 |
| PL2382474T3 (pl) | 2015-08-31 |
| TWI440854B (zh) | 2014-06-11 |
| CO6390020A2 (es) | 2012-02-29 |
| AU2010206195A1 (en) | 2010-07-29 |
| SG173065A1 (en) | 2011-08-29 |
| NZ593749A (en) | 2012-05-25 |
| ZA201105271B (en) | 2012-03-28 |
| CN102292638A (zh) | 2011-12-21 |
| HUE025015T2 (en) | 2016-04-28 |
| KR20110116016A (ko) | 2011-10-24 |
| PT2382474E (pt) | 2015-06-03 |
| IL213098A0 (en) | 2011-07-31 |
| EP2382474A1 (en) | 2011-11-02 |
| JP2012515893A (ja) | 2012-07-12 |
| DK2382474T3 (en) | 2015-04-07 |
| JP5379243B2 (ja) | 2013-12-25 |
| SG196837A1 (en) | 2014-02-13 |
| TW201031917A (en) | 2010-09-01 |
| RU2011134415A (ru) | 2013-02-27 |
| BRPI1006901A2 (pt) | 2016-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| He et al. | High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma | |
| HRP20150470T1 (hr) | Topljivi icam-1 kao biomarker za predviđanje terapijskog odgovora | |
| Peng et al. | Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma | |
| Lin et al. | Neuropilin 1 (NRP1) is a novel tumor marker in hepatocellular carcinoma | |
| BR112015023140A2 (pt) | proteínas de fusão il-22 fc, método para fabricar a proteína de fusão il-22 fc monomérica, composição, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar uma proteína de fusão il-22 fc, composições farmacêuticas e usos de uma composição farmacêutica | |
| WO2012170438A3 (en) | HUMAN ANTIGEN BINDING PROTEINS THAT BIND TO A COMPLEX COMPRISING β-KLOTHO AND AN FGF RECEPTOR | |
| BR112014030797A2 (pt) | epítopo de peptídeo isolado, proteína recombinante, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o epítopo de peptídeo ou mutante do mesmo, vacina de proteína, uso do epítopo de peptídeo ou mutante do mesmo, vacina de gene, uso da molécula de ácido nucléico, composição farmacêutica, anticorpo monoclonal e um fragmento de ligação ao antígeno do mesmo, linha de célula de hibridoma, kit, método para detecção da presença ou nível da proteína hbsag em uma amostra e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo | |
| WO2006052788A3 (en) | Detection of activation of endothelial cells as surrogate marker for angiogenesis | |
| CN101988926A (zh) | 一种高尔基蛋白gp73的夹心elisa定量检测方法及其检测试剂盒 | |
| Giorgio et al. | The ectopic FOF 1 ATP synthase of rat liver is modulated in acute cholestasis by the inhibitor protein IF 1 | |
| RU2013106938A (ru) | Биомаркеры в плазме крови, предназначенные для комбинированных терапий с использованием бевацизумаба при лечении рака молочной железы | |
| Borentain et al. | Inhibition of E-selectin expression on the surface of endothelial cells inhibits hepatocellular carcinoma growth by preventing tumor angiogenesis | |
| Feng et al. | Protein profile in HBx transfected cells: a comparative iTRAQ-coupled 2D LC-MS/MS analysis | |
| ITMI20092154A1 (it) | Marcatore biochimico serico | |
| Schwarz et al. | A novel monoclonal antibody immunoassay for the detection of human serum hepcidin | |
| Chen et al. | Chinese herbal medicine suppresses invasion-promoting capacity of cancer-associated fibroblasts in pancreatic cancer | |
| Heo et al. | Serum anti-EIF3A autoantibody as a potential diagnostic marker for hepatocellular carcinoma | |
| EP3216460B1 (en) | Antigen polypeptide for detecting plasma immunological marker-vegfr1 autoantibody and use thereof | |
| Pang et al. | Preoperative levels of serum interleukin-6 in patients with hepatocellular carcinoma | |
| JP2007521015A5 (hr) | ||
| Lee et al. | Modulation of HIF-1α and STAT3 signaling contributes to anti-angiogenic effect of YC-1 in mice with liver fibrosis | |
| Auweter et al. | Oxysterol-binding protein (OSBP) enhances replication of intracellular Salmonella and binds the Salmonella SPI-2 effector SseL via its N-terminus | |
| Markov et al. | Tight junction proteins contribute to barrier properties in human pleura | |
| BR112017022205A2 (pt) | anticorpo anti-vegfr2 humano para terapia de câncer antiangiogênica e objetivada | |
| JP2012515893A5 (hr) |